CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma

• Published in: Tumor biology 2018-02, Vol.40 (2), p.1010428318760420-1010428318760420
• Main Authors: Shirasu, Hiromichi, Ono, Akira, Omae, Katsuhiro, Nakashima, Kazuhisa, Omori, Shota, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Endo, Masahiro, Nakajima, Takashi, Takahashi, Toshiaki
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adenocarcinoma of Lung; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antigens; Antigens, Neoplasm - metabolism; Authorship; Biomarkers, Tumor - metabolism; Cancer therapies; Carcinoembryonic antigen; Carcinoembryonic Antigen - metabolism; Chemotherapy; Clinical medicine; Disease-Free Survival; Enzymes; Epidermal growth factor; ErbB Receptors - metabolism; Ethics; Female; Follow-Up Studies; Histology; Humans; Immunoassay; Immunotherapy; Keratin-19 - metabolism; Lung cancer; Lung carcinoma; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Male; Middle Aged; Monoclonal antibodies; Multivariate analysis; Mutation; Nivolumab; Non-small cell lung carcinoma; Patients; Pharmaceuticals; Research funding; Retrospective Studies; Smoking; Squamous cell carcinoma; Statistical analysis; Targeted cancer therapy; Tumors
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1177/1010428318760420

CYFRA 21-1 is a prognostic marker for non–small cell lung cancer. The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. This study aimed to examine whether CYFRA 21-1 has predictive implications for nivolumab therapy in patients with advanced lung adenocarcinoma. Of the 79 patients who were treated with nivolumab therapy at the Shizuoka Cancer Center between December 2015 and September 2016, we retrospectively reviewed the data of 50 patients. The patient characteristics were as follows: age